Rhelion Life Sciences Settles $100K Debt via Share Issuance and Grants Stock Options
Rhelion Life Sciences Corp. (CSE:RHEL) announced plans to settle approximately $100,000 in debt by issuing 3,333,333 shares at $0.03 per share, pending final approval from the Canadian Securities Exchange. The company also granted 2,300,000 stock options priced at $0.05 per share with a five-year expiry term, vesting over a 12-month period. Additionally, Dr. Robin Carhart-Harris was reappointed as Scientific Advisor.
The debt-for-share transaction allows the biotechnology firm to clean up its balance sheet following the acquisition of Filament. While issuing new shares to eliminate debt reduces cash obligations, it results in equity dilution for current shareholders. The newly granted stock options aim to retain key personnel and align incentives close to current market levels, as the stock traded at 0.025 CAD.
Investors will monitor regulatory approval from the exchange to finalize the debt settlement. Moving forward, potential catalysts for the company include further integration steps, regulatory updates, and progress on clinical trials that could expand commercial opportunities for PEX010.
Key points
- Rhelion Life Sciences Corp. will issue 3,333,333 shares at $0.03 to settle roughly $100,000 in debt, subject to exchange approval.
- The company granted 2,300,000 stock options at $0.05 per share, vesting over 12 months with a five-year term.
- Dr. Robin Carhart-Harris was reappointed as Scientific Advisor to support ongoing research and development efforts.
- The share-for-debt agreement facilitates post-acquisition balance sheet cleanup following the integration of Filament.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
How is Rhelion Life Sciences settling its debt?
Rhelion Life Sciences Corp. is settling approximately $100,000 in debt by issuing 3,333,333 common shares at a price of $0.03 per share, subject to approval from the Canadian Securities Exchange.
What stock options were granted by Rhelion Life Sciences?
The company granted 2,300,000 stock options at an exercise price of $0.05 per share. The options vest over 12 months and carry a five-year expiry term.
Who was reappointed as Scientific Advisor at Rhelion?
Dr. Robin Carhart-Harris was reappointed as Scientific Advisor to Rhelion Life Sciences Corp.